Before surgery
If treatment is given before surgery, HPH MRD may indicate how well it is working.
Background
What is ctDNA?
Tumor cells can release tiny fragments of their genetic material into the bloodstream – circulating tumor DNA (ctDNA). After treatment, very small amounts of cancer cells can remain (minimal residual disease, MRD). HPH MRD detects matching ctDNA with a test tailored to the individual tumor.
When can HPH MRD help?
The test can provide additional information at several points in your treatment.
Monitor response
HPH MRD can help show how well immunotherapy or chemotherapy is working.
After surgery
MRD testing may help assess whether residual disease remains after surgery.
Follow-up
Recurrence may be detected earlier than with conventional methods.
About the test
How does the test work? →
Your physician orders the test, a blood sample is taken, a personalized assay is built in the lab, and the result is returned to your physician.
Is the test painful? →
The blood draw is similar to a routine blood test and is usually only briefly uncomfortable.
Is HPH MRD a screening test? →
No. HPH MRD is not a screening test for healthy people.
Does it replace other tests? →
No. It complements existing diagnostics and follow-up and does not replace them.
How often is testing done? →
Your care team decides – often as part of planned follow-up or treatment monitoring.
Downloads & service
Guide
Plain-language explanation of what the test can do and how results can support conversations with your care team.
Download PDFMore information
You can reach us via the following contact details.
☎ +49 (0) 40 707085-200